Jefferies Financial Group Inc. Buys Shares of 103,900 LivaNova PLC (NASDAQ:LIVN)

Jefferies Financial Group Inc. purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 103,900 shares of the company’s stock, valued at approximately $4,812,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Russell Investments Group Ltd. boosted its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the period. Summit Investment Advisors Inc. lifted its stake in LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after acquiring an additional 289 shares in the last quarter. Xponance Inc. boosted its holdings in LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after acquiring an additional 445 shares during the period. Mariner LLC grew its position in LivaNova by 8.4% in the 4th quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after acquiring an additional 446 shares in the last quarter. Finally, Invesco Ltd. increased its stake in LivaNova by 0.6% during the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company’s stock worth $5,158,000 after purchasing an additional 667 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LIVN has been the subject of several recent research reports. Stifel Nicolaus lowered their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Monday, March 17th. The Goldman Sachs Group lowered their target price on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Finally, Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $59.17.

LivaNova Trading Up 2.7%

LIVN opened at $45.23 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $63.57. The business’s 50 day moving average is $37.98 and its two-hundred day moving average is $45.04. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of 107.69 and a beta of 0.84.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.